We examined adherence to ten predefined evidence-based guidelines in six areas of care: dyslipidemia, diabetes, chronic kidney disease, hypertension, weight management, and smoking cessation care.
We selected this evidence using predefined key terms and a search strategy, including clear inclusion and exclusion criteria to select any empirical evidence.
There was also little evidence of predefined outcomes, partly due to a lack of published protocols.
For example, open questions include: For System-Dynamics and Bayesian Network models, we can transfer predefined player actions as "evidence" to populate and drive the models.
Animals were excluded from the protocol on fulfillment of two predefined criteria, namely: (1) evidence on CT of lung injury to the left lung following acid instillation (i.e., model failure); or (2) malfunctioning of the injection pumps (i.e., non-delivery of Ang 1-7)).
The primary entry criteria for the study are subjects who (1) meet DSM-IV criteria for OCD as their primary diagnosis; (2) have evidenced a predefined partial response to an adequate trial of an SRI (as defined below); and (3) still have residual OCD symptoms severe enough to warrant additional treatment, as measured by a score 16 or above on the CY-BOCS (see Table 1).
More importantly, each statement is accompanied by a predefined 6-scale grade of force and evidence for the recommendation, which helps the reader in distinguishing between opinion and proof.
This study found no evidence of an increased risk of any of the extensive predefined list of adverse events related to pregnancy.
Conclusion In women given pertussis vaccination in the third trimester, there is no evidence of an increased risk of any of an extensive predefined list of adverse events related to pregnancy.
Data were abstracted using a predefined coding guide and synthesized from both qualitative and quantitative studies to examine evidence of moderation.
In the current phase II study as well as in the randomised phase II study (McDermott et al, 2008), both conducted in a first-line setting and at similar mean daily sorafenib doses (623.1 mg and 640.5 mg, respectively), the sorafenib/dacarbazine combination demonstrated some evidence of activity regardless of failure of both to meet the predefined objectives.
